Pacific Biosciences Of California Stock News

PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.

PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.

HiFiViral Solution helps to accelerate understanding of the Omicron variant, providing information that is important to public health response HiFiViral Solution helps to accelerate understanding of t

Strs Ohio cut its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 39.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,600 shares of the biotechnology companys stock after selling 13,400 shares during the period. Strs Ohios holdings in []

Vontobel Holding Ltd. raised its position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 8.1% during the third quarter, HoldingsChannel reports. The firm owned 74,714 shares of the biotechnology companys stock after purchasing an additional 5,583 shares during the period. Vontobel Holding Ltd.s holdings in Pacific Biosciences of California were worth $1,909,000 at the end []

Pacific Biosciences of California, Inc. (NASDAQ:PACB) shares reached a new 52-week low on Friday . The company traded as low as $18.36 and last traded at $18.49, with a volume of 18304 shares traded. The stock had previously closed at $19.26. Separately, Canaccord Genuity initiated coverage on shares of Pacific Biosciences of California in a []

Pacific Biosciences of California, Inc. (NASDAQ:PACB) dropped 6.4% during trading on Thursday . The company traded as low as $20.59 and last traded at $20.59. Approximately 169,064 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 2,959,062 shares. The stock had previously closed at $21.99. Separately, Canaccord Genuity []

During the last session, Pacific Biosciences of California Inc. (NASDAQ:PACB)s traded shares were 4.3 million, with the beta value of the company hitting 1.17. At the end of the trading day, the stocks price was $21.99, reflecting an intraday gain of 5.42% or $1.13. The 52-week high for the PACB share is $53.69, that puts Pacific Biosciences of California Inc. (NASDAQ: PACB) On Wednesday Up 15.28 Percent From Lows, What To Expect Going Ahead? Read More »

ARK Genomic ETF: Likely Economic Victim With Low Institutional Interest

Assenagon Asset Management S.A. trimmed its stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 59.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,541 shares of the biotechnology companys stock after selling 47,457 shares during the quarter. Assenagon Asset Management []

PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.

Pacific Biosciences of California Inc. (NASDAQ:PACB) price closed lower on Monday, December 06, dropping -1.37% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Invesco Ltd. reduced its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 93.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 81,295 shares of the biotechnology companys stock after selling 1,100,243 shares during the quarter. Invesco Ltd.s holdings in []